Pnd21 Product Enhancements Decrease the Incidence of Injection Site Reactions and Pain Resulting in Improved Adherence to Therapy in Patients With Multiple Sclerosis

Scanzillo, J; Bennett, Robert E.; Biancucci, P; Divan, V.; Sherman, Stuart; Al‐Sabbagh, Ahmad

doi:10.1016/s1098-3015(10)68820-1

Cited by 1 publication

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…13,14,21,22 Injection-site pain and injection anxiety were significantly lower in patients who used an autoinjector for IFNβ-1a IM versus manual injection. 102 Patients receiving IFNβ-1b reported greater satisfaction with a new application system that included a thinner, preattached needle and easier preparation of and changes to the autoinjector system versus the current application system.…”

Section: Product Enhancements and Adherencementioning

confidence: 99%

“…The first step requires patients to be educated and trained in proper injection technique and informed about the strategies available to manage ISRs before starting a DMD. Common strategies to minimize ISRs include warming medication to room temperature, 1 using autoinjectors, 13,14 rotating injection sites, and using a site map. Fear and pain associated with injections can be minimized by the use of local anesthetics, topical analgesics, and brief application of ice before each injection.…”

Section: Disease-modifying Therapies Ifnβ β and Glatiramer Acetatementioning

confidence: 99%

“…13,[99][100][101] Patients participating in an IFNβ-1b disease management program had a 10% higher rate of adherence to IFNβ-1b therapy over 1 year than those who did not participate. 99 Adherence was also improved during the same period in patients who used a 24-hour nurse hotline.…”

Section: Expectation Of Therapymentioning

confidence: 99%

See 2 more Smart Citations

Review: Optimizing Adherence to Multiple Sclerosis Therapies

B¹,

Lucas²,

Kresa-Reahl³

et al. 2008

International Journal of MS Care

View full text Add to dashboard Cite

Disease-modifying drugs (DMDs) have transformed the treatment of relapsing-remitting multiple sclerosis (RRMS). Several studies have shown the benefits of long-term treatment in RRMS; however, all multiple sclerosis (MS) therapies are associated with treatment-related tolerability and safety issues that may challenge patient compliance with therapy. Tolerability issues include flulike symptoms and injection-site reactions for interferon β(IFNβ) and lipoatrophy and systemic postinjection reactions for glatiramer acetate (GA). Altered blood cell counts, depression, and elevated liver enzymes, including rare cases of acute liver injury, are safety issues that have been associated with IFNβand, rarely, systemic anaphylactoid reactions with glatiramer acetate. Common tolerability issues associated with natalizumab are hypersensitivity and postinfusion reactions, and mitoxantrone may cause amenorrhea, nausea, and alopecia. Serious safety issues that have limited the use of natalizumab and mitoxantrone as first-line treatments are progressive multifocal leukoencephalopathy for natalizumab and cardiotoxicity and leukemia for mitoxantrone. Although both tolerability and safety issues can affect patient adherence to therapy, numerous strategies are available to manage tolerability and monitor safety issues. Through careful monitoring of treatment-related safety issues, patient education, and tolerability management strategies, treatment nonadherence can be minimized, thereby maximizing the treatment benefits of DMDs.

show abstract

Section: Product Enhancements and Adherencementioning

confidence: 99%

Section: Disease-modifying Therapies Ifnβ β and Glatiramer Acetatementioning

confidence: 99%